Skip to main content
. 2019 Apr 11;24(8):1095–1102. doi: 10.1634/theoncologist.2018-0695

Figure 2.

image

Kaplan‐Meier estimated progression‐free survival (PFS) curves by biomarker status. (A): PFS by treatment arm in the biomarker population. (B): PFS by HRG status in the control arm patients. (C): PFS by treatment arms for the HRG‐positive patients. (D): PFS by treatment arm for the HRG‐negative patients.

Abbreviations: E, erlotinib arm; HRG, heregulin; S+E, seribantumab + erlotinib arm.